Identifying effect modifiers of systemic hydrocortisone treatment initiated 7-14 days after birth in ventilated very preterm infants on long-term outcome: secondary analysis of a randomised controlled trial

Halbmeijer, N.M.; Sonnaert, M.; Swarte, R.M.; Koopman-Esseboom, C.; Stuijvenberg, M. van; Tollenaer, S.M.D.; ... ; SToP-BPD Study Grp (2023)

Article / Letter to editor

Objective To explore clinical effect modifiers of systemic hydrocortisone in ventilated very preterm infants for survival and neurodevelopmental outcome at 2 years' corrected age (CA).Design Secondary analysis of a randomised placebo-controlled trial.Setting Dutch and Belgian neonatal intensive care units.Patients Infants born <30 weeks' gestational age (GA), ventilator-dependent in the second week of postnatal life.Intervention Infants were randomly assigned to systemic hydrocortisone (cumulative dose 72.5 mg/kg; n=182) or placebo (n=190).Main outcome measures The composite of death or neurodevelopmental impairment (NDI) at 2 years' CA and its components. Candidate effect modifiers (GA, small for GA, respiratory index, sex, multiple births, risk of moderate/severe bronchopulmonary dysplasia or death) were analysed using regression models with interaction terms and subpopulation treatment effect pattern plots.Results The composite outcome was available in 356 (96.0%) of 371 patients (one consent withdrawn). For this outcome, treatment effect heterogeneity was seen across GA subgroups (<27 weeks: hydrocortisone (n=141) vs placebo (n=156), 54.6% vs 66.2%; OR 0.61 (95% CI 0.38 to 0.98); >= 27 weeks: hydrocortisone (n=30) vs placebo (n=31), 66.7% vs 45.2%; OR 2.43 (95% CI 0.86 to 6.85); p=0.02 for interaction). This effect was also found for the component death (<27 weeks: 20.1% vs 32.1%; OR 0.53 (95% CI 0.32 to 0.90); =27 weeks: 28.1% vs 16.1%; OR 2.04 (95% CI 0.60 to 6.95); p=0.049 for interaction) but not for the component NDI. No differential treatment effects were observed across other subgroups.Conclusion This secondary analysis suggests that in infants <27 weeks' GA, systemic hydrocortisone may improve the outcome death or NDI, mainly driven by itscomponent death. There was insufficient evidence for other selected candidate effect modifiers.

• Neonatology
• Infant Development
• Respiratory Medicine

• All authors: Halbmeijer, N.M.; Sonnaert, M.; Swarte, R.M.; Koopman-Esseboom, C.; Stuijvenberg, M. van; Tollenaer, S.M.D.; Tan, R.N.G.B.; Mohns, T.; Bruneel, E.; Steiner, K.; Kramer, B.W.; Debeer, A.; Weissenbruch, M.M. van; Marechal, Y.; Blom, H.; Plaskie, K.; Offringa, M.; Merkus, M.P.; Onland, W.; Leemhuis, A.G.; Kaam, A.H. van; SToP-BPD Study Grp
• Date: 2023-09-17
• Journal: Archives of Disease in Childhood. Fetal and Neonatal Edition
• Volume: 109
• Pages: F159 - F165
• DOI: doi:10.1136/archdischild-2023-325558
• Link: https://fn.bmj.com/content/109/2/159